Novartis Pharmaceuticals Corporation et al v. Fresenius Kabi USA, LLC et al
| Astex Therapeutics Ltd. and Novartis Pharmaceuticals Corporation |
| Fresenius Kabi USA, LLC and Fresenius Kabi AG |
| 1:2021cv00870 |
| June 17, 2021 |
| US District Court for the District of Delaware |
| Leonard P Stark |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 20, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Pro Hac Vice Attorney Jill K. MacAlpine for Astex Therapeutics Ltd., Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Pro Hac Vice Attorney Megan L. Meyers for Astex Therapeutics Ltd., Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Pro Hac Vice Attorney John D. Livingstone for Astex Therapeutics Ltd.,for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers (Associated Cases: 1:21-cv-00981-LPS, 1:21-cv-00870-LPS. (myr) |
Filing 13
SO ORDERED, re (8 in 1:21-cv-00981-LPS, 12 in 1:21-cv-00870-LPS) MOTION for Pro Hac Vice Appearance of Attorney Barbara R. Rudolph, Jill K. MacAlpine, Andrew E. Renison, John D. Livingstone, M. David Weingarten, Megan L. Meyers, and Shannon M. Patrick filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd.. Signed by Judge Leonard P. Stark on 7/8/2021. Associated Cases: 1:21-cv-00870-LPS, 1:21-cv-00981-LPS(etg)
|
| Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Barbara R. Rudolph, Jill K. MacAlpine, Andrew E. Renison, John D. Livingstone, M. David Weingarten, Megan L. Meyers, and Shannon M. Patrick - filed by Astex Therapeutics Ltd., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
SO ORDERED, re #11 STIPULATION TO EXTEND TIME the Deadline for Defendant Fresenius Kabi USA, LLC's Deadline to Answer, Move or Otherwise Respond to the Complaint to August 27, 2021 filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd. Signed by Judge Leonard P. Stark on 6/30/21. (ntl)
|
| Filing 11 STIPULATION TO EXTEND TIME the Deadline for Defendant Fresenius Kabi USA, LLC's Deadline to Answer, Move or Otherwise Respond to the Complaint to August 27, 2021 - filed by Astex Therapeutics Ltd., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 10 WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd.: For Fresenius Kabi AG waiver sent on 6/28/2021, answer due 8/27/2021. (Silver, Daniel) |
| Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Filing 9 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd.. Fresenius Kabi USA, LLC served on 6/21/2021, answer due 7/12/2021. (Silver, Daniel) |
| Filing 8 Summonses Issued (please complete the top portion of the form and print out for use/service). (apk) |
| Filing 7 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka America, Inc., Corporate Parent Otsuka Pharmaceutical Co., Ltd., Corporate Parent Otsuka Holdings Co., Ltd. for Astex Therapeutics Ltd. filed by Astex Therapeutics Ltd.. (apk) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (apk) |
| Filing 5 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,416,136 ;9,868,739 ;10,799,506. (apk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,324,225 ;8,415,355 ;8,685,980 ;8,962,630 ;9,193,732. (apk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Date of Expiration of Patent: (SEE ANDA FORM)Thirty Month Stay Deadline: 9/13/2024. (apk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Filing 1 COMPLAINT filed against Fresenius Kabi AG, Fresenius Kabi USA, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number BDEDC-3629921.) - filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd. (Attachments: #1 Exhibit A-H, #2 Civil Cover Sheet)(apk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
